Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer

Inclusion Criteria

• •Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information
• •Histologically or cytological evidence of locally advanced, biopsy-proven, stage II (inoperable), III-or oligometastatic stage IV NSCLC planned to be treated with chemoradiation with concurrent or adjuvant immunotherapy
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• •Adequate organ and marrow laboratory values for radiation therapy deemed by appropriate the investigator obtained within 14 days prior to registration for protocol therapy
• •Women of childbearing potential (WOCBP) must obtain a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \[HCG\]) at day -30 to day 0
• •Women of childbearing potential must be willing to abstain from heterosexual activity or use an effective method of contraception during the time of the study period
• •Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year